糖尿病合并心力衰竭老年患者SGLT2抑制剂应用研究进展

Progress in Use of SGLT2 Inhibitors in Elderly Patients with Diabetes Mellitus Combined with Heart Failure

糖尿病及心力衰竭是老年人常见病、多发病,由于存在多种共同危险因素,两种疾病常共存,且预后不佳。钠-葡萄糖共转运蛋白2(sodium-glucose cotransport protein 2,SGLT2)抑制剂是一种新型降糖药物,近年大型临床试验证实其不仅可降低血糖,还具有改善心力衰竭预后、保护肾功能等作用。对于多病共存的老年患者,合理使用此类药物可有效改善疾病预后。综述了SGLT2抑制剂的药理作用、作用机制、适用范围及老年患者用药注意事项等,以期为此类药物合理应用提供参考。

Diabetes mellitus and heart failure are common and frequent diseases among the elderly.Due to the presence of multiple common risk factors,the two diseases often co-exist and have a poor prognosis.Sodium-glucose cotransport protein 2 inhibitors are a new type of hypoglycaemic drug that has been shown in recent large clinical trials to not only lower blood glucose,but also protect renal function and improve the prognosis of heart failure.In elderly patients with multiple coexisting diseases,the rational use of these drugs can effectively improve the prognosis of the disease.This paper reviews the pharmacological effects,mechanism of action,scope of application and considerations for the use of sodium-glucose cotransport protein 2 inhibitors in the elderly,with the aim of promoting the rational use of these drugs in the elderly population,improving the prognosis of the disease and enhancing the quality of life of elderly patients.